vix.ing · top · new · best · stats · spec

No Modulation of the Effect of Aspirin by Body Weight in Healthy Older Men and Women

2020/03/30 by Robyn L. Woods, Galina Polekhina, Rory Wolfe +9 · 1 citation
Medicine · #Antiplatelet Therapy and Cardiovascular Diseases #Pharmacology and Obesity Treatment #Diabetes Treatment and Management

paper · pdf · doi:10.1161/circulationaha.119.044142

openalex publication_date 2020/03/30 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/01

Abstract

aging aspirin body weight A recent meta-analysis 1 of individual patient data from several randomized, controlled trials evaluating aspirin for the prevention of primary or secondary cardiovascular events found that the protective effect of low-dose aspirin (100 mg) was limited to individuals weighing <70 kg, driven by lean body mass (LBM) but not body mass index (BMI). 1 Given the limited number of people 70 years of age who were included in the meta-analysis 1 and calls for validation of these findings, 2,3 we investigated whether body habitus modulated the efficacy of aspirin in a post hoc analysis of the ASPREE trial (Aspirin in Reducing Events in the Elderly). SPREE randomized 19 114 older participants to daily 100-mg enteric-coated aspirin (9525) or matched placebo (9589) and followed them up for a median of 4.7 years for disability-free survival and other clinical outcomes. Trial participants were community-dwelling Australian (16 703) and US (2411) men and women who were 70 years of age at enrollment or 65 years of age for US blacks and Hispanics. Individuals were required to be free of any chronic illnesses likely to limit survival to <5 years and free of documented cardiovascular or cerebrovascular disease or high risk of bleeding. Anthropometric data, including body weight, height (deriving BMI as weight/height 2 and LBM from sex-specific weight and height 1 ), and waist circumference, were obtained for each participant. ASPREE had multiple Institutional Ethics Review Committee approvals in Australia and the United States. All ASPREE participants provided informed consent. ASPREE was registered at ClinicalTrials.gov (https://www.clinicaltrials.gov; NCT01038583).

Citations

Cited by